molecules of the month

potent, selective, Q2W IV CD73 inhibitor

completed Ph. I in HV, in dev. for cancer imm.

from opt. of known nucleotide CD73 inh.

J. Med. Chem., Jul. 20, 2020

Arcus Biosciences, Hayward, CA